Quantcast
Last updated on April 19, 2014 at 13:20 EDT

ThromboGenics Starts Trading as Part of the BEL20 Index Today

March 18, 2013

LEUVEN, Belgium, March 18, 2013 /PRNewswire/ –

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company
focused on developing and commercializing innovative ophthalmic medicines, announces that
the Company will start trading as part of the BEL20 index on the Euronext stock exchange
today.

The BEL20 index is a real-time index reflecting the continuous price evolution of the
20 most liquid Belgian shares listed on Euronext Brussels and serves as Blue-chip index
for Euronext Brussels. The weight of the index constituents is based on their market
capitalization adjusted for free float by using a free float banding system.

ThromboGenics will be included in the BEL20 index as of today.

Patrik De Haes, CEO of ThromboGenics, commented, “We are very pleased to be now
included in the BEL20 index which reflects the tremendous progress ThromboGenics has made
since its inception. The inclusion in the index will further increase the Company’s access
to a broader pool of investors and enhance ThromboGenics’ already strong profile as one of
the leading biotechnology companies in Europe.”

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing and
commercializing innovative ophthalmic medicines. The Company’s lead product,
JETREA(R)(ocriplasmin), has been approved by the US FDA for the treatment of symptomatic
VMA and was launched in January 2013. In Europe, it has been approved for the treatment of
vitreomacular traction (VMT), including when associated with macular hole of diameter less
than or equal to 400 microns.

In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for
the commercialization of JETREA(R) outside the United States. Under this agreement,
ThromboGenics could receive up to a total of EUR375 million in up-front and milestone
payments. It will receive significant royalties from Alcon’s net sales of JETREA(R).
ThromboGenics and Alcon intend to share the costs equally of developing JETREA(R) for a
number of new vitreoretinal indications.

ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), formerly
referred to as TB-403, for the treatment of ophthalmic and oncology indications.

ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin, NJ (US)
and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under
the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such
forward-looking statements are based on current expectations, and, accordingly, entail and
are influenced by various risks and uncertainties. The Company therefore cannot provide
any assurance that such forward-looking statements will materialize and does not assume an
obligation to update or revise any forward-looking statement, whether as a result of new
information, future events or any other reason. Additional information concerning risks
and uncertainties affecting the business and other factors that could cause actual results
to differ materially from any forward-looking statement is contained in the Company’s
Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase
of securities or assets of ThromboGenics in any jurisdiction. No securities of
ThromboGenics may be offered or sold within the United States without registration under
the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom,
and in accordance with any applicable U.S. state securities laws.

        For further information please contact:

        Wouter Piepers, Global Head of Corporate Communications
        +32-16-75-13-10 / +32-478-33-56-32
        wouter.piepers@thrombogenics.com

        Dr. Patrik De Haes, CEO
        +32-16-75-13-10
        Patrik.dehaes@thrombogenics.com

        Chris Buyse, CFO
        +32-16-75-13-10
        Chris.buyse@thrombogenics.com

        Citigate Dewe Rogerson
        David Dible/ Nina Enegren/ Sita Shah
        Tel: +44-20-7638-9571
        sita.shah@citigatedr.co.uk

        The Trout Group (US investor relations)
        Todd James/ Simon Harnest
        Tel: +1-646-378-2926
        tjames@troutgroup.com

SOURCE ThromboGenics NV


Source: PR Newswire